Literature DB >> 20536450

Overexpression of the natural tetrapeptide acetyl-N-ser-asp-lys-pro derived from thymosin beta4 in neoplastic diseases.

Jian-Miao Liu1, Maria-Concepcion Garcia-Alvarez, Jerome Bignon, Michal Kusinski, Krzysztof Kuzdak, Andrew Riches, Joanna Wdzieczak-Bakala.   

Abstract

The natural tetrapeptide acetyl-ser-asp-lys-pro (AcSDKP) is formed in vivo by enzymatic cleavage of the N terminus of thymosin beta4 by prolyl oligopeptidase (POP). Recently, AcSDKP was shown to promote angiogenesis. Because of the critical role of neovascularization in cancer development, the levels of AcSDKP and POP activity in a number of different malignant tissues were investigated. Our studies revealed that AcSDKP levels were markedly elevated in neoplastic diseases including hematologic malignancies and solid neoplasms. Consistent with this finding, the enhanced activity of POP was also detected in all analyzed specimens of cancer tissues. Both these novel findings are in concert with the previously reported overexpression of thymosin beta4 in a large variety of malignant tumors and with its potential role in cancerogenesis. The physiological relevance of these findings awaits further studies; however, our first results strongly suggest a key role for AcSDKP in the pathogenesis of cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536450     DOI: 10.1111/j.1749-6632.2010.05488.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  14 in total

Review 1.  The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.

Authors:  Takako Nagai; Kyoko Nitta; Megumi Kanasaki; Daisuke Koya; Keizo Kanasaki
Journal:  Clin Exp Nephrol       Date:  2014-07-01       Impact factor: 2.801

2.  Ac-SDKP suppresses TNF-α-induced ICAM-1 expression in endothelial cells via inhibition of IκB kinase and NF-κB activation.

Authors:  Liping Zhu; Xiao-Ping Yang; Branislava Janic; Nour-Eddine Rhaleb; Pamela Harding; Pablo Nakagawa; Edward L Peterson; Oscar A Carretero
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-03-04       Impact factor: 4.733

3.  Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia.

Authors:  Haiwu Cao; Xiaohong Zhao; Shiyun Lu; Zhi Wang
Journal:  Exp Ther Med       Date:  2018-04-30       Impact factor: 2.447

4.  Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats.

Authors:  Lei Zhang; Lei-Ming Xu; Yuan-Wen Chen; Qian-Wen Ni; Min Zhou; Chun-Ying Qu; Yi Zhang
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

5.  Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Tamyra D Downs; Patrick A McKee
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

6.  Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

Authors:  Megumi Kanasaki; Takako Nagai; Munehiro Kitada; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2011-11-30

Review 7.  N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Authors:  Keizo Kanasaki; Takako Nagai; Kyoko Nitta; Munehiro Kitada; Daisuke Koya
Journal:  Front Pharmacol       Date:  2014-04-14       Impact factor: 5.810

8.  Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Kenneth W Jackson; Victoria J Christiansen; Vivek R Yadav; Robert Silasi-Mansat; Florea Lupu; Vibhudutta Awasthi; Roy R Zhang; Patrick A McKee
Journal:  Neoplasia       Date:  2015-01       Impact factor: 5.715

9.  AcSDKP regulates cell proliferation through the PI3KCA/Akt signaling pathway.

Authors:  Ping Hu; Bin Li; Wenhua Zhang; Yijian Li; Guang Li; Xinnong Jiang; Joanna Wdzieczak-Bakala; Jianmiao Liu
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

10.  Preventive and therapeutic effects of thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis.

Authors:  Enrico Conte; Evelina Fagone; Elisa Gili; Mary Fruciano; Maria Iemmolo; Maria Provvidenza Pistorio; Daniela Impellizzeri; Marika Cordaro; Salvatore Cuzzocrea; Carlo Vancheri
Journal:  Oncotarget       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.